Company ProfilePremium

ANG Lifesciences India Limited

Company Profile Analysis

Ticker: 540694.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
ANG Lifesciences India Limited - Company showcase

Year Founded & Workforce

2006

ANG Lifesciences India Limited logo

ANG Lifesciences India Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

ANG Lifesciences India Limited Overview

ANG Lifesciences India Limited is an Amritsar-headquartered micro-cap manufacturer of finished pharmaceutical formulations, built around sterile dry-powder injection vials across beta-lactam, non-beta-lactam, cephalosporin and carbapenem lines, produced at Baddi in Himachal Pradesh, India's largest formulation cluster. It sells through four channels — government and institutional tenders, third-party (contract) manufacturing, direct marketing to hospitals and doctors via stockists, and exports to Africa, the Gulf and other rest-of-world markets — and since April 2021 has owned a printing and packaging subsidiary acquired out of insolvency for backward integration. The company enjoyed a pandemic-era surge to ₹354 Cr consolidated revenue and ₹40 Cr profit in FY2022, but revenue has since contracted to ~₹93 Cr with four consecutive annual losses. FY2026 audit disclosures flagged ₹25.86 Cr of defaults to HDFC Bank, and its bank-facility rating has fallen from BBB to C. It is today a distressed, promoter-controlled turnaround candidate rather than a growth franchise.


Company's own description

The company's annual reports describe its business as the manufacturing and marketing of finished pharmaceutical formulations in the dosage form of sterile dry-powder injection vials, with dedicated areas, machinery and equipment for beta-lactam and non-beta-lactam products under GMP norms (company summary reproduced by IIFL and Kotak Neo). The FY2025 annual report, as summarised by Screener.in, places the company within the "ANG Group", described as a WHO-GMP certified consortium of pharmaceutical companies, manufacturing finished formulations in non-beta-lactam, beta-lactam, cephalosporin and carbapenem segments. The FY2023 annual report states the vision of reaching every hospital with quality critical-care products and a mission of affordable medicines globally (Annual Report FY2022-23, pp. 3–4).

Infomerics' rating rationale (Aug 2026, Sep 2025, Feb 2024) gives a broader product description: dry-powder injections, liquid injections, capsules, tablets, ointments and syrups, with the plant on Baddi–Nalagarh Road and ISO 9001:2008 certification.

Business model and revenue model

Product model (≈99% of FY2026 consolidated revenue): manufacture-and-sell of branded/generic finished formulations. Revenue is product sales; no material service, subscription or licensing income is disclosed.

Contract manufacturing: "third-party manufacturing" is cited as one of four market segments (Screener.in business summary of annual report), i.e., ANG manufactures formulations under other marketers' brands — a fee/transfer-price model embedded in product revenue.

  • Printing & packaging (≈1–9% of revenue depending on year, derived): Mansa Print & Publishers produces mono-cartons, printed paper, corrugated boxes and aluminium blister foils, sold partly to ANG (inter-segment) and partly to third parties.

Value chain position

ANG sits in the formulation (finished dosage form) stage of the pharmaceutical value chain: it buys active pharmaceutical ingredients (APIs — e.g., sterile cephalosporin and carbapenem powders, typically sourced from Indian/Chinese API makers; specific suppliers not disclosed), fills them aseptically into vials, packages and distributes. The Mansa acquisition moved it one step upstream into secondary packaging, which management said represents about 15–20% of formulation product cost (company filing quoted by AL Circle, 3 Apr 2021).

Customer types and end-markets

Channel (as described by company)Customer typeCommercial characteristic
InstitutionalCentral/state government hospitals, procurement corporations, defence/railway/PSU hospitals (specific named buyers not disclosed)Tender-based, price-driven, long receivable cycles
Third-party manufacturingPharma marketing companiesVolume contracts, thin margins
Direct marketingHospitals and doctors, via stockists (since 2014-15)Branded generics, better margins, field-force dependent
ExportsAfrica, Gulf countries, other ROWRegistration-dependent, semi-regulated markets
Printing & packaging (Mansa)Pharma companies in the Baddi cluster, including ANGJob-work/converter economics

Source: Screener.in summary of annual report; IIFL company summary.

Independent characterisation

ANG is best understood as a sub-scale, institution-heavy sterile antibiotics filler whose economics are dominated by working capital rather than by IP or brands. Three features stand out. First, extreme volatility: revenue rose from ₹154 Cr (FY2021) to ₹354 Cr (FY2022) and then fell 74% to ₹93 Cr (FY2025), indicating that the FY2022 peak was driven by pandemic-period critical-care injectable demand rather than durable share gains (the specific products driving FY2022 are not identified in sources reviewed). Second, working-capital intensity: debtor days rose from 105 (FY2022) to 267 (FY2026) and the cash conversion cycle from 51 to 238 days (Screener.in), consistent with slow-paying institutional customers and/or stressed collections. Third, financial distress: interest consumes all operating profit, banks report defaults, and the company has stopped cooperating with its rating agency. The investable question is therefore not growth but solvency and restructuring.

Strategy

Stated strategy (themes from company disclosures)

The latest annual report and MD&A could not be retrieved directly. Themes consistently present in company-sourced material are:

  1. Critical-care hospital reach — the FY2023 annual report vision centres on supplying quality critical-care products to every hospital.

  2. Affordable medicines globally — the mission statement emphasises affordability and international supply.

  3. Backward integration — the Mansa acquisition was framed as securing packaging supply and reducing a cost component worth 15–20% of product cost (AL Circle, Apr 2021).

  4. Channel diversification across institutional, contract manufacturing, direct marketing and exports (annual report business description per Screener.in).

  5. Expansion in semi-regulated export markets (Africa, Gulf, ROW).

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)

No new business launches, partnerships, platform investments, cost programmes with quantified targets, or ESG commitments were announced on BSE in the period, based on the announcement records reviewed (ScanX; Screener.in; Business Standard). Observable actions are defensive:

Deleveraging from operating cash: ₹11 Cr operating cash flow in FY2026 directed to ₹12 Cr net financing outflow.

Capex freeze: implied net capex of ~₹0 in FY2026.

Cost containment: FY2026 operating expenses fell to ₹90 Cr from ₹94 Cr on flat revenue, lifting EBITDA from -₹1 Cr to +₹3 Cr.

Statutory dues clearance: management stated it had paid income-tax dues flagged by the FY2025 auditor and referred to ₹53.45 lakh of EPF dues (Directors' Report FY2025, IIFL reproduction).

Guidance and medium-term targets

The company has not issued public revenue, margin or debt guidance in the last 24 months, and no earnings call has been held since August 2022 (Screener.in concall list). Infomerics has repeatedly cited the company's failure to provide information since November 2023.

Products & Services

The company does not publish a public SKU-level price list in the sources reviewed, and specific brand names were not verifiable. The catalogue below is organised by segment and dosage platform, using the company's own category disclosures.

Pharmaceuticals segment — Dosage platforms

PlatformDescription / capabilityTarget customerSincePricing modelSource
Sterile dry-powder injection vials (core)Aseptically filled powder for reconstitution; dedicated areas and equipment for beta-lactam and non-beta-lactam lines under GMPHospitals, government institutions, contract clients, export2008-09Tender prices (institutional); trade prices to stockists; contract transfer pricesIIFL; Kotak Neo
Liquid injectionsSmall-volume parenteralsAs above——Infomerics
CapsulesOral solid———Infomerics
TabletsOral solid———Infomerics
OintmentsTopical———Infomerics
SyrupsOral liquid———Infomerics

Pharmaceuticals segment — Technology blocks (injectables)

BlockWhat it coversWhy it mattersSource
Beta-lactam (penicillins)Penicillin and penicillin + beta-lactamase inhibitor combinationsRegulatory requirement for segregated facilities creates a modest entry barrierScreener.in AR summary; Groww
CephalosporinsCephalosporin dry-powder injectionsHigh-volume hospital antibiotics; intensely tender-competedScreener.in AR summary
CarbapenemsCarbapenem dry-powder injectionsHigher-value reserve antibiotics for resistant infectionsScreener.in AR summary; Groww
Non-beta-lactamOther dry-powder injectables (see therapeutic categories)Broadens hospital basketScreener.in AR summary

Therapeutic categories disclosed

Antibiotics; antivirals; antimalarials; anti-ulcer agents; carbapenems; corticosteroids; penicillins; and beta-lactamase inhibitor combinations (Groww company profile based on company disclosures). Representative molecules in these categories in the Indian injectable market (for example ceftriaxone, meropenem, piperacillin-tazobactam, pantoprazole, artesunate, methylprednisolone, acyclovir) are cited for orientation only and are not confirmed as ANG SKUs.

Printing & Packaging segment (Mansa Print & Publishers)

ProductDescriptionTarget customerSource
Mono-cartonsPrinted folding cartons for unit packsANG and Baddi-cluster pharma companiesScreener.in
Paper printingInserts, labels, leafletsAs aboveScreener.in
CorrugationShipper/outer corrugated boxesAs aboveScreener.in
Aluminium foils (blister foils)Printed foil for blister packsOral solid manufacturersScreener.in; AL Circle

Flagship offerings, launch years, version history and list prices: not publicly disclosed.

Financial Narrative

All figures consolidated, ₹ Cr, fiscal years ending 31 March (Source: Screener.in consolidated statements compiled from BSE filings, accessed 19 Oct 2026; FY2025 and FY2026 net profit precise values from FY2026 results coverage, Whalesbook, May 2026). FY2022 is the first consolidated year (Mansa acquired 1 Apr 2021).

Income statement

Table 6.1 — Income statement (₹ Cr)

Diluted EPS equals basic EPS (no dilutive instruments disclosed). FY2023 PBT includes ₹10 Cr other income, without which the year would have been loss-making at the pre-tax level. FY2026 consolidated PBT was ₹(1,301.07) lakh (Investywise).

Dividends: Screener.in shows a 3% dividend payout for FY2022 and nil for all other years.

Margins and growth

Table 6.2 — Margins (%)

Revenue CAGR: FY2022–FY2026 (4 years) = -28.4%; FY2021–FY2026 (5 years) = -9.6% (derived from ₹154 Cr FY2021 to ₹92.89 Cr FY2026; Screener.in reports -10%).

Standalone cross-check (Infomerics, audited)

Table 6.3 — Standalone key financials (₹ Cr)

Source: Infomerics press releases, 21 Feb 2024 and 29 Sep 2025. FY2026 standalone: revenue ₹91.60 Cr, PBT ₹(5.19) Cr, PAT ₹(4.73) Cr (Whalesbook; Investywise). Infomerics also reported standalone interest coverage of 0.98x (FY2024) and -0.25x (FY2025).

Balance sheet

Table 6.4 — Balance sheet as at 31 March (₹ Cr)

Notes and gaps:

Cash & equivalents: not separately disclosed in sources reviewed; annual net cash flow has been approximately zero every year (Screener.in), indicating minimal free cash. Net debt is therefore approximated by gross borrowings (₹79 Cr at Mar 2026).

Short-term vs long-term debt split: not publicly disclosed in sources reviewed. The rated bank facilities (Infomerics, 24 Aug 2026) indicate the structure: cash credit ₹39.50 Cr (short-term, revolving), term loans ₹0.97 Cr, ₹1.94 Cr and ₹6.75 Cr (the last maturing Nov 2027), plus non-fund-based bank guarantee ₹5.00 Cr and letter of credit ₹15.00 Cr. Borrowings above the rated ₹49.16 Cr fund-based limit (~₹30 Cr at Mar 2026) likely include unsecured/promoter or other loans — composition not disclosed.

Goodwill & intangibles: not publicly disclosed.

Working capital and current ratio: not publicly disclosed in sources reviewed. Screener.in "working capital days" moved from 20 (FY2022) to 72 (FY2025) and -8 (FY2026); the negative FY2026 figure reflects stretched payables and statutory dues rather than efficiency.

Open charges: registered with MCA: ₹81.62 Cr (TheCompanyCheck). Contingent liabilities: ₹15.7 Cr (Screener.in, latest annual report).

Cash flow

Table 6.5 — Cash flow (₹ Cr)

Notes: FY2022 investing outflow of ₹44 Cr coincides with the Mansa acquisition and capacity investment. The FY2024 investing inflow of ₹20 Cr and ₹30 Cr fall in fixed assets indicate an asset sale (not detailed in sources).

Ratios

Table 6.6 — Return, leverage and efficiency ratios

Notes: ROCE for FY2022 is not reported by Screener.in (shown as 0 to preserve the chartable format; treat as not available). FY2025 debt/EBITDA is mathematically negative because EBITDA was negative — economically "not meaningful". Screener.in reports FY2026 ROE as -16% on an average-equity basis; ROIC is not publicly disclosed (ROCE is the closest proxy).

Quarterly trajectory (consolidated, ₹ Cr)

Table 6.7 — Last 13 quarters

Source: Screener.in quarterly consolidated results compiled from BSE filings. TTM to Jun 2026: sales ₹83.6 Cr, net loss ₹13.3 Cr, EPS -₹10.21.

Commentary on trends, inflections and drivers

FY2022 peak (inflection up). Revenue more than doubled to ₹354 Cr and EBITDA margin reached 19%, coinciding with exceptional pandemic-period hospital demand for injectable antibiotics, antivirals and corticosteroids. The company itself did not attribute the surge to specific products in sources reviewed, but the subsequent symmetrical collapse strongly suggests non-recurring demand rather than structural share gains. Comparable small injectable makers in Punjab show the same pattern: Kwality Pharmaceuticals' revenue fell 45% in FY2023 after a FY2022 spike (StockAnalysis), indicating an industry-wide normalisation.

FY2023–FY2025 (contraction). Revenue fell 38%, 34% and 36% in successive years. Fixed costs did not fall proportionately, so EBITDA margin compressed from 19% to -1.6%, and with ₹9–12 Cr of annual interest the company slipped into persistent pre-tax losses from FY2024. Working capital deteriorated sharply: inventory days rose from 59 to 331 and debtor days from 105 to 262, meaning that the company was carrying roughly 2.5–3 years' worth of combined inventory and receivables relative to its shrunken sales by FY2025, financed by stretching payables to 405 days.

FY2026 (stabilisation, not recovery). Revenue was flat (₹92.89 Cr) and EBITDA turned modestly positive (₹3 Cr, 2.8%), helped by a strong Q4 FY2026 (EBITDA margin 11.4%). Operating cash flow of ₹11 Cr was used to repay ₹12 Cr of financing, and borrowings fell to ₹79 Cr. However, interest (₹8 Cr) still exceeded EBITDA nearly threefold, and the auditor flagged defaults.

Q1 FY2027 (relapse). Sales fell 38% YoY to ₹15.30 Cr — the weakest quarter in the 13-quarter series — with EBITDA margin of -12.8% and net loss of ₹4.24 Cr (Business Standard / Capital Market, 15 Aug 2026), prompting the August 2026 rating downgrade to C. Equity has fallen from ₹86 Cr (FY2023) to ₹53 Cr (FY2026); at the TTM loss rate, book value would erode by roughly a quarter per year absent a capital infusion.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipBusinessLocation

ANG Lifesciences India Ltd

Listed parent

Pharmaceutical formulations

Amritsar (RO) / Baddi (plant)

Mansa Print & Publishers Ltd (incorporated 5 Aug 2003)

Wholly owned subsidiary since 1 Apr 2021

Printing & packaging (mono-cartons, printed paper, corrugation, aluminium blister foil)

Baddi, Himachal Pradesh

Revenue by Segment and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025FY2026

Consolidated revenue (INR Cr)

3542201459392.89

Pharmaceuticals revenue — standalone proxy (INR Cr)

348.67207.01131.3789.9191.60

Printing & Packaging external revenue — derived (INR Cr)

5.3312.9913.633.091.29

Pharmaceuticals share of revenue (%)

98.594.190.696.798.6

Printing & Packaging share of revenue (%)

1.55.99.43.31.4

Pharmaceuticals revenue growth YoY (%)

126.4-40.6-36.5-31.61.9

Standalone (Pharma) net profit (INR Cr)

39.72-0.66-8.65-10.34-4.73

Consolidated net profit (INR Cr)

40.00-0.26-10.15-12.41-11.08

Subsidiary and consolidation effect on net profit — derived (INR Cr)

0.280.40-1.50-2.07-6.35

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

3542201459392.89

Operating expenses (INR Cr)

2862051359490

EBITDA / operating profit (INR Cr)

681510-13

Depreciation (INR Cr)

69876

EBIT — derived EBITDA less depreciation (INR Cr)

6262-8-3

Other income (INR Cr)

110-12-1

Interest expense (INR Cr)

9121198

Profit before tax (INR Cr)

543-11-16-13

Net profit (INR Cr)

40-0.26-10.15-12.41-11.08

EPS basic (INR)

31.02-0.20-7.77-9.50-8.49

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

19.26.86.9-1.62.8

EBIT margin — derived (%)

17.52.71.4-8.6-3.2

PBT margin (%)

15.31.4-7.6-17.2-14.0

Net margin (%)

11.3-0.1-7.0-13.3-11.9

Revenue growth YoY (%)

129.9-37.9-34.1-35.9-0.1

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Total operating income (INR Cr)

348.67207.01131.3789.91

EBITDA (INR Cr)

65.0911.079.12-1.81

PAT (INR Cr)

39.72-0.66-8.65-10.34

Total debt (INR Cr)

60.9952.7555.7767.80

Tangible net worth (INR Cr)

83.4882.8173.7363.12

EBITDA margin (%)

18.675.356.94-2.01

Overall gearing (x)

0.730.640.761.07

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

1013131313

Reserves (INR Cr)

7373635140

Total equity (INR Cr)

8386766453

Total borrowings (INR Cr)

7771738379

Other liabilities (INR Cr)

130119928278

Total assets (INR Cr)

290276241230210

Net fixed assets (INR Cr)

9388585751

Other assets incl. receivables, inventory, cash (INR Cr)

198188183172160

Implied trade receivables — derived from debtor days (INR Cr)

101.883.273.166.867.9

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operating activities (INR Cr)

2526-9011

Cash from investing activities (INR Cr)

-44-920-21

Cash from financing activities (INR Cr)

20-17-102-12

Net cash flow (INR Cr)

00000

Free cash flow as reported by Screener (INR Cr)

-17169-411

Implied capex net of disposals — derived (INR Cr)

4210-1840

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on closing equity — derived (%)

48.2-0.3-13.4-19.4-20.9

ROA — derived (%)

13.8-0.1-4.2-5.4-5.3

ROCE as reported (%)

091-4-2

Debt to equity (x)

0.930.830.961.301.49

Gross debt to EBITDA (x)

1.14.77.3-83.026.3

Interest coverage EBIT/interest — derived (x)

6.90.50.2-0.9-0.4

Asset turnover (x)

1.220.800.600.400.44

Debtor days

105138184262267

Inventory days

59118183331288

Days payable

113165254405317

Cash conversion cycle (days)

5191113189238

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales (INR Cr)

56.4633.2618.5537.8418.4132.8824.7316.8224.6026.0518.7323.5015.30

EBITDA (INR Cr)

6.541.66-1.913.36-1.712.28-2.15-0.700.650.08-2.682.68-1.95

EBITDA margin (%)

11.584.99-10.308.88-9.296.93-8.69-4.162.640.31-14.3111.40-12.75

Interest (INR Cr)

2.312.292.513.842.082.182.002.421.941.891.932.182.24

PBT (INR Cr)

2.36-2.63-6.36-4.08-4.14-1.29-6.38-3.89-2.73-3.21-5.96-1.10-5.58

Net profit (INR Cr)

1.75-2.32-5.93-3.65-3.07-2.09-5.19-2.06-2.01-2.95-4.75-1.38-4.24

EPS (INR)

1.34-1.78-4.54-2.80-2.35-1.60-3.97-1.58-1.54-2.26-3.64-1.06-3.25

Region Overview

RegionStatusChannel

India

Core market (majority of revenue per GuruFocus)

Institutional tenders, third-party manufacturing, direct to hospitals/doctors via stockists

Africa

Export market

Distributors / registrations

Gulf countries

Export market

Distributors / registrations

Other rest of world

Export market

—

“—” = not publicly disclosed.

Share Price & Returns

HorizonReturnSource

1 year

+22%

Screener.in

3-year CAGR

-19%

Screener.in

5-year CAGR

-36%

Screener.in

52-week range

₹17.6 – ₹49.7

Screener.in

5-year high (adjusted)

~₹640 (during the FY2022 boom)

Sharpely (12 Aug 2026; adjusted for bonus)

Valuation Multiples

MultipleANGBasisPeer reference (Value Research; TTM)

P/E

Not meaningful (TTM EPS -₹10.21)

Screener.in

Shilpa 70.0x; Caplin 30.1x; Pfizer 24.0x; Eris 25.6x

P/B

~0.93x (book ₹40.5)

Screener.in

Shilpa 7.7x; Caplin 5.5x; Pfizer 4.0x; Eris 4.1x

EV (derived)

~₹128 Cr (market cap ₹49.3 Cr + borrowings ₹79 Cr; cash not deducted)

Derived

—

EV/Sales

~1.5x on TTM sales ₹83.6 Cr

Derived

—

EV/EBITDA

Not meaningful (TTM EBITDA ~-₹2 Cr)

Derived

—

Long-term by Date

DateLong-term (₹49.16 Cr fund-based)Short-term (₹20 Cr non-fund-based)

4 Jun 2021

IVR BBB- / Stable

IVR A3

1 Sep 2022

IVR BBB / Stable

IVR A3+

28 Nov 2022

IVR BBB- / Stable

IVR A3

8 Jun 2023

IVR BB+ / Negative

IVR A4+

16 Nov 2023

IVR BB / Negative

IVR A4

30 Nov 2023

IVR BB / Negative / INC

IVR A4 / INC

21 Feb 2024

IVR BB- / Negative / INC

IVR A4 / INC

21 Aug 2024

IVR B+ / Negative / INC

IVR A4 / INC

29 Sep 2025

IVR B / Negative / INC

IVR A4 / INC

24 Aug 2026

IVR C / Negative / INC

IVR A4 / INC

Debt Facilities

FacilityAmount (INR Cr)Maturity

Cash credit

39.50

Revolving (annual renewal)

Term loan 1

0.97

July 2023 (latest maturity details not available — likely overdue/extended)

Term loan 2

1.94

August 2024 (latest maturity details not available)

Term loan 3

6.75

November 2027

Bank guarantee (non-fund)

5.00—

Letter of credit (non-fund)

15.00—

Analyst Conclusions

Management guidance and consensus

Management has issued no quantitative guidance and holds no earnings calls; there is no analyst consensus. The observable trajectory is: FY2026 revenue flat at ₹92.89 Cr with EBITDA of ₹3 Cr; Q1 FY2027 revenue down 38% YoY with a ₹4.24 Cr loss; TTM revenue ₹83.6 Cr and loss ₹13.3 Cr.

Bull case

  1. Operating leverage on idle capacity: the same asset base produced ₹68 Cr EBITDA in FY2022; Q4 FY2026 (11.4% EBITDA margin) shows that even a modest volume recovery restores positive operating profit. Contract-manufacturing wins could swing EBITDA meaningfully on a ₹90–120 Cr revenue base.

  2. Balance-sheet resolution optionality: a settlement with HDFC Bank or a promoter/strategic capital infusion would remove most of the ~₹8 Cr interest drag; at ~0.93x book and ~1.5x EV/sales, the equity is priced for distress.

  3. Asset value: segregated sterile beta-lactam/cephalosporin/carbapenem capacity in Baddi is scarce and regulatory-gated; a larger player could find acquisition cheaper than greenfield construction.

Bear case

  1. Default trajectory: ₹25.86 Cr already in default, rating at C, interest exceeding EBITDA, and negligible free cash — the base case risk is lender enforcement or insolvency, in which equity holders could be heavily impaired.

  2. Structural uncompetitiveness: peers Kwality (₹503 Cr, ~24% EBITDA margin) and Venus (₹770 Cr, ~19%) are scaling with regulatory upgrades and R&D, while ANG shows no capex, no R&D and declining volumes.

  3. Governance and transparency: absent internal auditor, rating non-cooperation, 44.9% promoter pledge, and a loss-making subsidiary with opaque economics reduce confidence that reported assets (₹68 Cr receivables, high inventory) are fully realisable.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
By ~14 Nov 2026Q2 FY2027 results — does revenue recover toward ₹25 Cr/quarter, and is EBITDA positive?
OngoingAny disclosure of lender action, one-time settlement, restructuring, or IBC application
OngoingPromoter pledge changes or invocation; any promoter fund infusion or preferential issue
OngoingInfomerics next review (rating at C — next step is D, i.e., default)
Feb 2027Q3 FY2027 results; receivable and inventory trends
May 2027FY2027 audited results and auditor's report (going-concern language, default status, internal audit)
OngoingMansa Print & Publishers — impairment, divestment or closure
OngoingRevised Schedule M compliance and any regulatory inspection outcomes at Baddi

Analyst verdict

ANG Lifesciences is a case study in how a small sterile-injectables manufacturer can be lifted by a demand shock and then left stranded when it fades. In FY2022 the company generated ₹354 Cr of consolidated revenue, a 19% EBITDA margin and ₹40 Cr of profit; four years later it reports ₹93 Cr of revenue, a 2.8% EBITDA margin, an ₹11 Cr loss, a 238-day cash conversion cycle, and an auditor's disclosure of ₹25.86 Cr in defaults to its principal lender. Its bank-facility rating has slid nine notches from BBB to C in three years, largely under "issuer not cooperating" status — itself a red flag about management transparency.

The industry is not the explanation. A same-city peer, Kwality Pharmaceuticals, suffered a similar post-pandemic revenue collapse yet doubled revenue to ₹503 Cr by FY2026 through regulatory upgrades and portfolio investment; Venus Remedies grew to ₹770 Cr with double-digit margins. ANG, by contrast, has frozen capex, discloses no R&D, and has watched its packaging subsidiary shrink to near-zero external sales while widening consolidated losses.

The equity's appeal rests on optionality: sterile capacity that is hard to replicate, a price below book value, and evidence from Q4 FY2026 that margins recover quickly with volume. But that optionality is subordinate to creditors. With interest roughly three times EBITDA, net worth falling by ₹11–13 Cr a year, and Q1 FY2027 revenue down 38%, the realistic paths are a lender-negotiated settlement backed by fresh promoter or strategic capital, or a formal insolvency process. Absent a disclosed recapitalisation plan, the risk-reward is unfavourable for minority shareholders. Our assessment is High Risk / Distressed — Avoid pending a credible debt-resolution and capital-infusion announcement; the key signals to change that view would be cured defaults, a rating upgrade off C, and two consecutive quarters of positive EBITDA above ₹2 Cr per quarter.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleOn board sincePrior roles / other boardsEducationAgeSource

Rajesh Gupta (DIN 01423407)

Founder, Managing Director (MD since 1 Oct 2016)

14 Jun 2006

Director of Mansa Print & Publishers, ANG Healthcare India Pvt Ltd, Les Reins Lifesciences Pvt Ltd and other promoter entities (11 active directorships); former director RN Chemicals & Pharmaceutical Pvt Ltd

Undergraduate degree, Thapar University (1993)

~52–53 (52 per Simply Wall St, 2025)

Tofler; MarketScreener; Simply Wall St

Saruchi Gupta (DIN 03618458)

Whole-time Director & CFO

1 Apr 2011

Director of Mansa Print & Publishers, Baddi Agro Pvt Ltd, ANG Innovative Products & Systems Pvt Ltd (9 active directorships)

——

Tofler; MarketsMojo

Sukhpal Singh

—

2 May 2016

———

TheCompanyCheck

Mrs. Chetna

Independent Director; re-appointed for a second 5-year term from 12 Oct 2026 to 11 Oct 2031

12 Oct 2021

———

BSE announcement 30 Sep 2026

Rohit Mittal

Director (retires by rotation, i.e., non-independent); re-appointed at 2026 AGM

11 Oct 2023

———

TheCompanyCheck; ScanX

Harvinder Singh Dhami

—

27 May 2024

———

TheCompanyCheck

“—” = not publicly disclosed.

Directors' Remuneration

ExecutiveLatest disclosed compensationPeriodSource

Rajesh Gupta (MD)

Total ~₹10.8 million (~₹1.08 Cr; ~US$126k), described as above the median for Indian companies of similar size

Latest year available to Simply Wall St (circa FY2025)

Simply Wall St

Rajesh Gupta (MD)

Remuneration approved value ₹54.00 lakh for H1 FY2023

H1 FY2023

BSE RPT disclosure, 25 Nov 2022

Independent directors

Sitting fees; amounts not publicly disclosed in sources reviewed

——

Board & Management Changes

DateChangeSource

11 Oct 2023

Rohit Mittal appointed director

TheCompanyCheck

27 May 2024

Harvinder Singh Dhami appointed director

TheCompanyCheck

7 Sep 2026

Board recommends Rohit Mittal's re-appointment by rotation and Chetna's second term

ScanX

30 Sep 2026

AGM approves both

BSE announcement

Governance Overview

MetricFY2022FY2023FY2024FY2025FY2026

Promoter holding (%)

71.1470.6070.6070.6070.60

Public holding (%)

28.8629.4029.3929.3929.40

Number of shareholders

4,2597,1636,8686,5085,952

Major Shareholders

HolderStakeNotes

Rajesh Gupta (promoter)

~70.41%

Direct holding (MarketsMojo; Simply Wall St)

Other promoter group (incl. Saruchi Gupta)

~0.19% (derived)

—

Promoter pledge/encumbrance

~44.9% of promoter holding

Screener.in

Foreign institutional investors

—

Screener.in shows no FII/DII category

Domestic institutions / mutual funds

—

As above

Retail and others

~29.4% across ~5,666 holders

Top non-promoter holders not publicly disclosed in sources reviewed

Competitive Landscape

Key Competitors

CompetitorHQOverlap with ANGRelative positioningKey data (verified)

Venus Remedies Ltd

Panchkula, Haryana

Critical-care injectables, antibiotics (incl. carbapenems), oncology; exports

Much larger, R&D-led, profitable

FY2026 revenue ₹769.60 Cr (+17.9%); PAT ₹102.79 Cr; OPM 19.1% (Capital Market, 27 May 2026)

Kwality Pharmaceuticals Ltd

Amritsar, Punjab

Injectables, beta-lactam, general formulations; same city of origin

Rapidly scaling; EU-GMP certified plants

FY2026 revenue ₹503.08 Cr (+35.9%); PAT ₹67.35 Cr; EBITDA margin ~24% (Capital Market; FilingReader)

Gland Pharma Ltd

Hyderabad

Sterile injectables (CDMO, regulated markets)

Global scale; different market tier

—

Caplin Point Laboratories / Caplin Steriles

Chennai

Injectables for emerging and regulated markets

Strong in LatAm/Africa

TTM revenue ₹2,287 Cr; net margin 28.1% (Value Research peer table)

Shilpa Medicare Ltd

Raichur, Karnataka

Injectables (oncology), CDMO

Larger, specialty

TTM revenue ₹1,682 Cr; net margin 16.2% (Value Research)

Nectar Lifesciences Ltd

Chandigarh/Punjab

Cephalosporin APIs and formulations

Larger cephalosporin integrator

—

Orchid Pharma Ltd

Chennai

Cephalosporin APIs/sterile

API-integrated

—

Brooks Laboratories Ltd

Baddi, HP

Dry-powder injectables (beta-lactam, cephalosporin)

Comparable micro-cap

—

Lyka Labs Ltd

Gujarat

Injectables

Comparable small-cap

—

Large-cap generics (Pfizer India, Eris Lifesciences, Alkem, Aristo — hospital antibiotic brands)

Various

Branded hospital antibiotics

Dominant brand and field-force scale

Pfizer TTM revenue ₹2,570 Cr; Eris ₹3,230 Cr (Value Research)

Packaging converters in the Baddi–Nalagarh cluster

Himachal Pradesh

Cartons, labels, foils (Mansa segment)

Fragmented, price-driven

Not compiled

Peer Comparison FY2026

MetricANG LifesciencesKwality PharmaceuticalsVenus RemediesShilpa Medicare (TTM)

Revenue (INR Cr)

92.89503.08769.601,682.47

Revenue growth YoY (%)

-0.135.917.9—

EBITDA / operating margin (%)

2.824.119.128.4

Net margin (%)

-11.913.413.416.2

R&D intensity (% of revenue)

——2.4—

Market cap (INR Cr)

49.3——20,803

“—” = not publicly disclosed.

Company Snapshot

$10.7M

Revenue

2006

Founded

SWOT Analysis

Strengths

  • Specialised sterile capability: dedicated beta-lactam, cephalosporin, carbapenem and non-beta-lactam dry-powder lines (FY2025 annual report via Screener.in), a regulatory barrier to casual entry.
  • Demonstrated operating leverage at scale: at ₹354 Cr revenue in FY2022 the business earned 19% EBITDA margin and ₹40 Cr profit (Screener.in), proving the asset base can be profitable when utilised.
  • Positive FY2026 operating cash flow: ₹11 Cr CFO used to reduce borrowings from ₹83 Cr to ₹79 Cr (Screener.in).
  • Stable controlling shareholder: promoter holding unchanged at 70.60% since FY2023 (Screener.in), with no dilution despite losses.
  • Captive packaging: Mansa supplies cartons and foils; ANG purchased ₹11.38 Cr from Mansa in H1 FY2023 alone (BSE RPT filing).
  • Cluster location: Baddi site within India's largest formulation hub (Infomerics), easing access to APIs, packaging and skilled labour.
  • Q4 FY2026 operating rebound: EBITDA margin 11.4% on ₹23.50 Cr sales (Screener.in) shows margin recovery is achievable at ~₹95 Cr annualised run-rate.

Weaknesses

  • Loan default: ₹25.86 Cr of interest/instalment defaults to HDFC Bank flagged by FY2026 auditor (Whalesbook).
  • Persistent losses: consolidated net losses of ₹10.15 Cr, ₹12.41 Cr and ₹11.08 Cr in FY2024–FY2026 (Screener.in).
  • Interest burden exceeds operating profit: FY2026 EBITDA ₹3 Cr vs interest ₹8 Cr; EBIT/interest -0.4x (derived).
  • Working-capital lock-up: debtor days 267, inventory days 288, CCC 238 days in FY2026 (Screener.in).
  • Governance and disclosure gaps: no internal auditor (FY2026 auditor), non-cooperation with rating agency since Nov 2023 (Infomerics), no earnings call since Aug 2022 (Screener.in).
  • Promoter pledge: ~44.9% of promoter shares encumbered (Screener.in), creating overhang and control risk.
  • Loss-making subsidiary: implied ₹6.35 Cr negative consolidation effect in FY2026 (derived) against ~₹1.3 Cr external packaging revenue.

Opportunities

  • Capacity re-utilisation via contract manufacturing: third-party manufacturing is an existing channel (annual report); filling idle sterile capacity for larger marketers could lift margins quickly, as Q4 FY2026 suggested.
  • Reserve-antibiotic demand: carbapenem and beta-lactamase-inhibitor injectables remain essential against resistant infections (category disclosures via Groww).
  • Export expansion: existing presence in Africa and the Gulf (IIFL) can be deepened with dossier filings.
  • Debt resolution: a one-time settlement or restructuring with HDFC Bank could cut the ~₹8 Cr annual interest drag, which alone exceeds FY2026 EBITDA.
  • Strategic investor or asset monetisation: price-to-book of ~0.93x (Screener.in) and Baddi sterile assets could attract a larger CDMO or marketer seeking injectable capacity.
  • Peer playbook: Kwality Pharmaceuticals went from a FY2023 trough of ₹251 Cr to ₹503 Cr in FY2026 via regulatory upgrades (FilingReader), showing a path for Punjab-origin injectable makers.

Threats

  • Lender enforcement: continued default could trigger recall, SARFAESI action or an insolvency application under IBC (risk inferred from default disclosure; no action reported).
  • Rating at C: IVR C/Negative (24 Aug 2026) indicates very high default risk and may restrict bank guarantees needed for tenders (Infomerics).
  • Revenue relapse: Q1 FY2027 sales -37.8% YoY to ₹15.30 Cr (Business Standard).
  • Price competition from scaled peers such as Venus (₹770 Cr revenue) and Kwality (₹503 Cr) with far lower cost of capital.
  • Regulatory compliance costs: revised Schedule M GMP upgrades require capex the company is not currently undertaking (implied FY2026 capex ~₹0).
  • Equity erosion: net worth fell from ₹86 Cr (FY2023) to ₹53 Cr (FY2026); at TTM loss of ₹13.3 Cr it could halve within ~2 years without a turnaround (derived).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Q4 FY2025 results: consolidated sales ₹16.82 Cr (-56% YoY); net loss ₹2.06 Cr Screener.in; IndMoneyFourth consecutive loss quarter; revenue trough
May 2025FY2025 results: consolidated revenue ~₹93 Cr; net loss ₹12.41 Cr; standalone loss ₹10.34 Cr Whalesbook; InfomericsThird consecutive annual loss
Aug 2025FY2025 annual report: auditor flags unpaid statutory dues; management says income-tax dues paid, EPF dues ₹53.45 lakh referenced Directors' Report (IIFL)Early signal of liquidity stress
14 Aug 2025Q1 FY2026 results: sales ₹24.60 Cr (+33.6% YoY); net loss ₹2.01 Cr HDFC Securities / Capital MarketBrief revenue recovery
16 Sep 2025AGM scheduled for 30 Sep 2025 HDFC SecuritiesRoutine
29 Sep 2025Infomerics downgrades to IVR B / Negative / INC; reaffirms A4; cites non-submission of informationCredit deterioration; governance signal
30 Sep 202519th AGM HDFC SecuritiesRoutine
10 Nov 2025Board meeting intimation for 14 Nov HDFC SecuritiesRoutine
14 Nov 2025Q2 FY2026 results: sales ₹26.05 Cr (-20.8% YoY); net loss ₹2.95 Cr; OPM 0.3% HDFC Securities / Capital MarketLosses persist
1 Jan 2026Trading window closed ahead of Q3 results ScanXRoutine
5 Feb 2026Board meeting intimation for 14 Feb ScanXRoutine
14 Feb 2026Q3 FY2026 results: consolidated net loss ₹4.75 Cr; standalone loss ₹497.70 lakh; standalone revenue ₹2,597.05 lakh vs ₹2,390.85 lakh; 9M standalone revenue ₹6,880.44 lakh vs ₹7,224.40 lakh; limited review unmodified ScanX; Screener.inWorst quarter of FY2026
Mar 2026Shareholder count falls to 5,952 (from 6,508 a year earlier) Screener.inRetail exit
22 May 2026Board meeting intimation for audited FY2026 results ScanXRoutine
30 May 2026FY2026 audited results: consolidated revenue ₹92.89 Cr, net loss ₹11.08 Cr; standalone revenue ₹91.60 Cr, loss ₹4.73 Cr Whalesbook; ScanXLoss narrows but remains large
30 May 2026Auditor highlights defaults of ₹25.86 Cr on HDFC Bank interest and instalments, unpaid statutory dues, and absence of an internal auditor WhalesbookMost material negative disclosure; default status
2 Jun 2026Q4 FY2026 detail: total income ₹23.67 Cr (+35.5% YoY); PBT -₹1.10 Cr; EBITDA margin 11.4% Kotak Neo; Screener.inBest operating quarter since Q1 FY2024
19 Jun 2026Trading window closure from 1 Jul 2026 announced ScanXRoutine
7 Aug 2026Board meeting intimation for Q1 FY2027 results ScanXRoutine
14 Aug 2026Q1 FY2027 results: sales ₹15.30 Cr (-37.8% YoY); net loss ₹4.24 Cr; OPM -12.8% Business Standard / Capital MarketSharp relapse
24 Aug 2026Infomerics downgrades long-term rating to IVR C / Negative / INC; reaffirms IVR A4 / INCRating now indicates very high default risk
7 Sep 2026Board meeting: FY2026 annual report; 20th AGM fixed for 30 Sep; book closure 24–30 Sep ScanX; InvestywiseRoutine
23 Sep 2026Trading window closed ahead of Q2 FY2027 results Screener.inRoutine
30 Sep 202620th AGM approves financials, Rohit Mittal re-appointment, cost auditor remuneration; Chetna re-appointed ID to Oct 2031 BSE via Screener.inBoard continuity
1 Oct 2026Scrutiniser's report filed BSE via Screener.inRoutine
16 Oct 2026Reg. 74(5) depository compliance certificate for Sep 2026 quarter; stock closes ₹37.8 (+4.5%) Screener.inShare price up ~22% over 1 year despite results
Oct 2026 (Sep quarter filing)Sep 2026 shareholding: promoters 70.60%, shareholders 5,666 Screener.inContinued retail attrition

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 3,540 Mn in FY2022 to INR 928.9 Mn in FY2026.
ANG Lifesciences India Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations3,5402,2001,450930928.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Screener.in — ANG Lifesciences consolidated and standalone financials, shareholding, documents and announcements (accessed 19 Oct 2026) (screener.in)
  2. Infomerics Ratings press releases: 24 Aug 2026 ( 29 Sep 2025 ( 21 Feb 2024 (: infomerics.com · infomerics.com · infomerics.com
  3. Whalesbook — FY2026 results and auditor concerns (May 2026)
  4. Investywise — FY2026 annual report summary (Sep 2026)
  5. Business Standard / Capital Market — Q1 FY2027 results (15 Aug 2026)
  6. Kotak Neo — Q4 FY2026 results (2 Jun 2026)
  7. HDFC Securities / Capital Market — Q1 and Q2 FY2026 results (Aug and Nov 2025)
  8. ScanX — corporate announcements (2026)
  9. IIFL — company summary, directors' report and auditor's report reproductions
  10. MarketsMojo — company CV (address, RTA, capital structure)
  11. TheCompanyCheck, Tofler, RegisterKaro — MCA director and company data
  12. Simply Wall St — management tenure and compensation
  13. MarketScreener — Rajesh Gupta profile
  14. AL Circle and PrintWeek — Mansa Print & Publishers acquisition (Apr 2021)
  15. BSE filings — Q3 FY2023 results (14 Feb 2023); RPT disclosure (25 Nov 2022); FY2022 results publication (Jun 2022); Annual Report FY2022-23
  16. ICICI Direct — corporate actions (bonus 1:4, Jul 2022)
  17. Groww, Kuvera, GuruFocus, Sharpely, Value Research — business description, segments, price history, peer comparisons
  18. Capital Market via Arihant, StockAnalysis, Anand Rathi — Venus Remedies FY2026
  19. Capital Market via Wealthy, FilingReader, Trade Brains, StockAnalysis — Kwality Pharmaceuticals FY2026

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.